Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?

AudioMedica News

Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Freek Verheugt

Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
Shamir Mehta: [audio:https://www.audiomedica.com/podcasting/08.Shamir_Mehta.mp3] Freek Verheugt: [audio:https://www.audiomedica.com/podcasting/09.Freek_Verheugt.mp3]

Click here for all the interviews from ESC 2005